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Abstract: The herpes simplex virus dsDNA genome is distinguished by an unusually high G+C nucleotide content. HSV-
1 and HSV-2, for instance, have GC contents of 68% and 70% respectively, while that of the host (human) genome is 
41%. To determine how GC content varies with genome location, GC content was measured separately in coding and in-
tergenic regions of HSV-1 DNA. The results showed that the 75 genes constitute a uniform population with a mean GC 
content of 66.9 ± 4.1%. In contrast, intergenic regions were found in two non-overlapping populations, one with a mean 
GC content (69.3 ± 4.6% n=32) similar to the coding regions and another where the GC content is lower (56.0 ± 4.9 
n=30). Compared to other regions of the genome, intergenic regions with reduced GC content were found to be enriched 
in local GC minima, CACACA sequences and a primary target sequence (TTAAAA) for retrotransposition events. The 
results are interpreted to suggest that a high GC content is part of the way HSV-1 protects its genes from invasion by mo-
bile genetic elements active during cell differentiation in the nervous system.  
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INTRODUCTION  
  The basic features of the herpes simplex virus (HSV-1) 
genome are now well known. Each virion contains a single 
molecule of dsDNA 152 kb in length. A total of 75 genes for 
known proteins are encoded with 69 of these present in a 
single copy and three in two copies each [1-3]. The genome 
is divided into two segments, L and S, which encode 57 
(UL) and 12 (US) single copy genes, respectively. The L and 
S segments are separated by repeated genes, which are also 
found at the genome ends (Fig. 1). As HSV-1 DNA is repli-
cated, the L and S segments invert with respect to each other 
yielding four genome “isomers” that are found in equal pro-
portions in wild-type HSV-1 populations [4-6].  
 
 
 
 
 
 
Fig. (1). Schematic drawing of the HSV-1 genome. The genome is 
152,261 bp in length and is divided into two segments, L and S. 
Each segment is organized with single copy genes (UL and US) in 
the middle and repeated genes (RL and RS) at the ends. 
 
  Among the genes encoded by HSV-1 are 43 ancestral or 
core genes present in all -, - and -herpesviruses [3, 7, 8]. 
All 43 are located in UL and most are conserved genes   
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involved in vital virus functions such as entry of the virus 
into a host cell, DNA replication, capsid assembly, packag-
ing DNA into the capsid and exit of the capsid from the host 
cell nucleus. The non-core HSV-1 genes include all US 
genes and highly divergent genes found at the segment ends 
[9]. Non-core genes encode proteins involved in lineage- or 
species-specific functions such as transcriptional transactiva-
tion, immune evasion and host cell recognition.  
  A high GC content is one of the most unusual features of 
the HSV-1 genome. HSV-1 and HSV-2 have GC contents of 
68% and 70%, respectively, while the value for the host 
(human) genome is 41%. In contrast, 54.4 ± 11.5% is the 
average GC content for the 44 herpesviruses whose genome 
sequences have been determined (as of March 2007). Only 
eight herpesviruses, all -herpesviruses, have GC contents of 
68% or greater. In an effort to understand the reason for the 
high GC content, I have focused on HSV-1 and examined 
the extent to which GC content varies with position in the 
genome. The GC content was determined in the coding re-
gions and in the regions between genes. The results have 
identified a group of intergenic regions whose GC content is 
reduced compared to the coding regions and to the genome 
as a whole.  
MATERIALS AND METHODOLOGY  
  The HSV-1 DNA sequence (NC_001806) was extracted 
from public databases and manipulated with programs in 
GCG (version 11.1.3; Accelrys) run on a Dell PowerEdge 
1950 server with dual 3 GHz Xeon cpu’s and 10GB of 
RAM). Composition was used to determine GC contents and 
FindPatterns+ was used to locate specific sequences. GC 
content in a sliding 120 bp window was determined with 
Artemis (Sanger Institute). Local GC minima were identified 
by visual inspection of the trace with all identified minima at 
least 10% GC lower than the adjacent background. 34    The Open Biochemistry Journal, 2007, Volume 1  Jay C. Brown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Histogram showing the GC content of HSV-1 genes (black bars) and intergenic regions (gray bars). Note the presence of a single 
population of coding region GC contents. Intergenic GC contents are considered to fall into two distinct groups, one coinciding with the 
population of genomic GC contents and the other with lower GC content. The two groups are identified as genome-like and reduced GC con-
tent, respectively. The 32 intergenic regions in the genome-like group have a mean GC content of 69.3% (range 62.1%-81.5%) while in the 
reduced GC content group the mean is 56.0% (30 regions; range 46.3%-61.7%; indicated by the horizontal gray line). Not represented in this 
analysis are the regions between the left genome end and RL1, and between the right genome end and RS1. 
 
Table 1.  GC Content of Coding and Intergenic Regions in the HSV-1 Genome 
 Coding  Region  Intergenic  
Region (rightward) 
 Coding  Region  Intergenic 
Region (rightward) 
Gene Length  (bp)  %GC Length  (bp)  %GC
a  Gene  Length (bp)  %GC  Length (bp)  %GC 
RL1    747 82.9  1003  68.1  UL36 9495 71.3    170  60.6 
RL2 (ex 2)  1604  77.2  5588  67.8  UL37  3373  69.3   448  68.3 
UL1    675 58.1    Overlap  UL38 1398 71.3    517  61.5 
UL2 1005  66.1    70  48.6  UL39 3414 65.7    70  74.3 
UL3   708  63.4   160  46.3  UL40 1023 61.4    221  53.4 
UL4    600 64.8   62  69.4  UL41 1470 62.7    477  62.7 
UL5  2649 62.1    Overlap  UL42 1526 66.8    111  55.0 
UL6  2031 68.3    Overlap  UL43 1305 72.4    280  62.1 
UL7   890  66.1   200  55.0  UL44 1516 67.8    187  57.8 
UL8  2253  70.4   238  72.7  UL45   519  68.6   247  56.7 
UL9  2555 63.5    Overlap  UL46 2157 71.1    84  67.9 
UL10 1445  65.3    154  53.2  UL47 2082 73.1    492  63.2 
UL11    291 66.6    Overlap  UL48 1473 65.1    370  64.3 
UL12  1881  68.5   60  66.7  UL49   906  70.5   Overlap 
UL13  1557  64.0   Overlap  UL49A  1276  68.9   18  50.0 
UL14    660 65.9   106  73.6  UL50 1116 66.7    153  48.4 HSV-1 G+C Content  The Open Biochemistry Journal, 2007, Volume 1    35 
(Table 1). Contd….. 
UL15 (ex 1)  1029  64.3   127  60.6  UL51   735  68.4   38  76.5 
UL16  1122 68.3   92  81.5  UL52 3177 66.1    Overlap 
UL17  2112 70.1   139  66.2  UL53 1017 61.1    540  64.6 
UL15 (ex 2)  1179  61.5   283  56.5  UL54 1539 69.3    225  60.0 
UL18   957  65.5   354  68.1  UL55   561  62.4   166  50.6 
UL19  4125  68.5   293  68.6  UL56   705  66.2  3766  68.3 
UL20   669  61.3   587  60.3 RL2  1604  77.2  1003  68.1 
UL21 1622  66.0    172  60.5 RL1    747  82.9  1375  77.3 
UL22 2517  66.7    291  60.8 RS1  3897  81.4  1537  74.6 
UL23  1304  63.5   Overlap  US1  1297  64.9   94  61.7 
UL24 1008  64.6    70  51.4  US2   876  64.3   295  65.1 
UL25 1743  68.0    255  60.0 US3  1446  63.6    78  61.5 
UL26 1908  71.4    343  47.8  US4   717  63.7   272  59.6 
UL27  3023  66.5   9  77.7  US5   279  65.9   411  58.6 
UL28  2358  69.7   305  66.6  US6  1185  64.3   183  60.6 
UL29  3591  67.3   755  63.3  US7  1173  65.6   287  56.1 
UL30  3708  65.8   Overlap  US8  1653  66.5   419  69.2 
UL31   921  65.6   Overlap  US9   273  63.0   573  57.1 
UL32  1791  68.0   Overlap  US10   939  67.3   Overlap 
UL33   393  67.9   81  70.4  US11   486  67.3   66  68.2 
UL34   828  67.1   107  67.3  US12   267  65.5  1549  75.1 
UL35   339  65.8   146  48.6 RS1  3897  81.4  1261  78.5 
aIntergenic regions with reduced GC content are highlighted. Others are in the genome-like group.  
RESULTS  
GC Content in Coding and Intergenic Regions 
  Coding and intergenic regions were extracted from the 
HSV-1 DNA sequence (NC_001806) using the editor func-
tion of GCG, and GC contents were determined with Com-
position. The 75 genes were found to have a mean GC con-
tent of 66.9 ± 4.1% with a range of 58.1% (UL1) to 82.9% 
(RL1; Table 1). Gene GC contents constituted a single popu-
lation centered at the mean value as shown in Fig. 2 (black 
bars). The GC contents of gene subgroups such as essential 
and non-essential genes or core and non-core genes were 
examined and found not to differ significantly from each 
other or from the genome as a whole (Table 2).  
  Compared to gene GC contents, intergenic regions were 
found to have a broader range of values, which extend from 
46.3% (UL3-UL4) to 81.5% (UL16-UL17). Intergenic re-
gion GC contents were considered to form two non-
overlapping populations as shown in Fig. 2 (gray bars). One 
coincided approximately with the distribution of gene GC 
contents while the other spanned a range of lower values. 
Further analysis was done with the two populations, which 
are identified as the genome-like GC content group (32 re-
gions) and reduced GC group (30 regions), respectively (Ta-
ble 1). Intergenic regions in the genome-like group had GC 
contents in the range of 62.1% (UL43)-81.5% (UL16); the 
range of the reduced GC group was 46.3% (UL3)-61.7% 
(US1).  
  Both genome-like and reduced GC intergenic regions are 
found throughout the HSV-1 genome (Table 1). In each case, 
however, there are areas of concentration. Reduced GC re-
gions, for instance, occur preferentially at three sites, UL20-
UL26, UL35-UL45 and US3-US7 that contain evolutionarily 
divergent genes (Table 1) [9]. In contrast, genome-like inter-
genic regions are enriched in two areas, UL16-UL20 and 
UL27-UL34, where evolutionarily conserved genes are con-
centrated (Table 1). Genome-like intergenic regions are also 
enriched between genes found near the genome ends and 
near the inter-segment junction.  
  The lengths of intergenic sequences vary from zero (i.e. 
overlapping genes) to several hundred base pairs (excepting 
very long intergenic regions that occur near the segment 
ends). Genome-like and reduced GC intergenic regions differ 
only slightly in average length, the values being 258.7±195.1 
and 230±138.8, respectively. Many reduced GC intergene 
lengths occur in a single population with a mean of approxi-
mately 150 bp, while genome-like lengths are more evenly 
distributed in the range of 0-600 bp (Fig. 3).  
Local GC Minima, CA Repeats and TTAAAA Sites 
  Inspection of intergenic sequences revealed additional 
features that distinguish genome-like from reduced GC re-
gions. For instance, measurement of GC content in a sliding 36    The Open Biochemistry Journal, 2007, Volume 1  Jay C. Brown 
window 120 bp in length showed that intergenic regions 
were often the sites of pronounced local minima in GC con-
tent. This feature is illustrated in Fig. 4, which shows the GC 
content in two regions of the genome. Local GC minima 
were found to occur, for instance, between UL42-UL43, 
UL43-UL44, and US5-US6, but not between US6-US7. The 
presence of local GC minima is indicated for intergenic re-
gions with genome-like and reduced GC content in Tables 3 
and  4, respectively. Of the 29 intergenic regions with re-
duced GC content, 19 were found to be sites of local GC 
minima while only 8 of 29 genome-like intergenic regions 
have the same feature.  
  The HSV-1 genome was examined for the frequency of 
two specific sequence motifs, CA repeats and TTAAAA 
sites. CA repeats are a common feature of the host (human) 
genome where they constitute 0.3% of the total sequence 
[10]. CA repeats occur predominantly as microsatellite 
DNA, but other functions have also been defined (see be-
low). In the HSV-1 genome the sequence CACACA was 
taken as an overall measure of the CA repeat frequency. It 
occurs 79 times, a value in excess of the statistical expecta-
tion for a random 68% GC genome (49; see Table 5). Com-
pared to the statistical expectation, CACACA sequences are 
enriched in intergenic regions; 17 are expected on a statisti-
cal basis and 24 are found (Table 5). Further, among the 24 
intergenic CACACA sequences, most (16) are found in re-
duced GC regions (Tables 4 and 5).  
  TTAAAA sequences were identified because these are 
prominent target sites for introduction of novel DNA by 
retrotransposition [11-14]. Such DNA inserts, including the 
long interspersed nuclear elements (LINE or L1 sequences) 
could affect the virus by inactivating it if incorporation was 
into a required gene. Retrotransposition could also affect the 
genome by introduction of a novel gene into the HSV-1 ge-
nome if incorporation follows reverse transcription of a cel-
lular mRNA [15-18].  
  Analysis demonstrated that the HSV-1 genome contains a 
total of 28 TTAAAA sequences, a value greater than the 
number expected on a statistical basis (Table 5). Eighteen 
occur in coding regions and 10 in intergenic segments. Of 
those in intergenic regions, 6 are found in reduced GC and 4 
in genome-like sequences (Tables 3 and 4). Of the four pre-
sent in genome-like intergenic regions, all are in intergenic 
segments (at the ends of UL and in US) that contain evolu-
tionarily divergent genes [9].  
DISCUSSION  
Intergenic Regions with Reduced GC Content 
  The high GC content observed for HSV-1 genes was 
fully expected in light of the high GC content of the genome 
as a whole and of the RL, RS, UL and US regions [2]. It was 
remarkable to notice, however, that coding region GC con-
Table 2.  Mean GC Content of Selected HSV-1 Gene Groups
a 
Gene group  Mean %GC ± SD  P value
b 
Essential 
Non-essential 
67.3 ± 3.9 (n=34) 
66.5 ± 4.3 (n=38) 
0.55 
Core 
Non-core 
66.7 ± 2.8 (n=43) 
67.3 ± 5.4 (n=38) 
0.39 
Beta kinetic class 
Gamma kinetic class 
65.5 ± 2.8 (n=13) 
66.5 ± 4.3 (n=38) 
0.87 
All UL 
All US 
66.6 ± 3.1 (n=58) 
65.2 ± 1.4 (n=12) 
0.91 
aSource: Essential, Non-essential, Beta (early) kinetic class, Gamma (late) kinetic class: [7]; Core, Non-core: [3]; UL, US: GenBank NC_001806.  
bApplies to the hypothesis that the GC content of the two gene groups is different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Histogram showing the lengths of HSV-1 intergenic re-
gions with genome-like GC content (top) and reduced GC content 
(bottom). Note the population of reduced GC intergenic lengths 
centered at ~150 bp. Excluded from this analysis are very long 
intergenic regions between RL1-RL2, RL2 (exon 2)-UL1, UL56-
RL2, RS1-US1 and US12-RS1.  HSV-1 G+C Content  The Open Biochemistry Journal, 2007, Volume 1    37 
tents occur in a single, relatively narrow distribution (Fig. 2). 
In view of the diversity of HSV-1 genes, it might have been 
expected that different populations would be observed corre-
sponding, for instance, to essential compared to non-
essential genes, UL compared to US genes, core compared to 
lineage specific genes or early (beta) compared to late 
(gamma) genes (see Table 2). The existence of a single 
population indicates that coding region GC content is af-
fected by factors that apply to all genes in a more or less 
equal way.  
  The greater diversity of GC contents in intergenic regions 
contrasts with the narrow distribution in the genes (Fig. 2). 
While some intergenic GC contents are similar to the genes 
and to the genome as a whole, there are others with lower 
GC contents. These are distributed over a wide range (~46%- 
~61%) as shown in Table 1 and Fig. 2. The presence of a 
reduced GC population of intergenic regions suggests that 
evolutionary forces constraining other sequences apply dif-
ferently in this case, and understanding the difference might 
be revealing about HSV-1 evolution, replication and patho-
genesis.  
High GC content in genes and the effects of L1 retro-
transposition 
  I suggest the high GC content of genes may be related to 
the way HSV-1 adapts to retrotransposition events in neu-
rons. HSV-1 enters the host by infecting epithelial cells, but 
it promptly traffics to neurons in local (trigeminal) ganglia 
where it establishes a latent infection that most often lasts for 
the lifetime of the host. The virus can be reactivated from 
neurons causing recurrent infections that are the hallmark of 
HSV-1 disease [19].  
  Neurons arise during development from progenitor cells 
that undergo a large-scale proliferation accompanied by gen-
eration of extensive cell diversity [20, 21]. Functioning neu-
rons are selected from this highly diverse population that 
may initially include 10
10 or more cell types. Selection is 
based on the activity of individual neurons. Those that be-
come incorporated into active networks survive while the 
others are lost. It is estimated that no more than 15%-40% of 
post-mitotic neurons survive this experience-based selection 
process [22-23].  
  Although the mechanisms used for generation of neu-
ronal cell diversity are not thoroughly understood, it is con-
sidered that retrotransposition by L1 elements plays a sig-
nificant role [23]. The human genome contains approxi-
mately 10
5 L1 elements (non-LTR retrotransposons) that 
together account for ~15% of the genome. Active L1 ele-
ments are 5 kb-6 kb in length, but most L1s are inactive due 
to 5’ deletions, rearrangements or mutations in the open 
reading frames. Only 80-100 human L1s are considered to be 
retrotransposition competent, and of these ~10% are consid-
ered to be highly active [11, 16].  
  Two genes, an endonuclease and reverse transcriptase are 
encoded in L1 retrotransposons, and transposition involves 
reverse transcription of the L1 mRNA. Reverse transcription 
takes place at specific sites in the host cell genome where 
primers are created following single-strand cuts introduced 
by the L1-encoded endonuclease. L1 elements are introduced 
at these sites, which occur preferentially at TTAAAA and 
related AT-rich sequences [11-14]. As a rare event, the L1 
reverse transcription machinery can act in trans on cellular 
mRNAs to introduce genes and processed pseudogenes at L1 
retrotransposition sites [17, 18].  
  In the developing nervous system, L1 retrotransposition 
can, in principle, contribute to generation of cell diversity by 
any process in which insertion of exogenous DNA can affect 
gene expression. Introduction into an exon, for instance, 
could block protein expression while similar insertion events 
could affect promoter function, alternative splicing or other 
processes. Recent studies have demonstrated that L1 retro-
transposition can promote other forms of genetic instability 
by way of the DNA repair machinery [11]. L1 retrotransposi-
tion has been observed experimentally in mice, in HeLa cells 
and in neural progenitor cells in culture [11, 24]. In the latter 
case, retrotransposition is found to be enhanced following 
downregulation of Sox2, a presumptive inhibitor of L1 mo-
bility [24]. 
  It is suggested that a high GC content is a part of the way 
HSV-1 protects itself from harmful effects that might result 
from L1 insertion, particularly insertion into genes. A high 
GC content is expected to minimize the number of 
TTAAAA and other AT-rich insertion sites present in genes 
and therefore to protect the genes from L1 retrotransposition 
events. Such protection would be particularly beneficial in 
the case of latently infected cells where the number of HSV-
1 genomes is reduced compared to lytic infections [25]. The 
proposed high rate of L1 retrotransposition in neurons makes 
a high GC content particularly attractive for viruses such as 
HSV-1 that replicate and establish latent infections in neu-
rons. It is consistent with this idea to note that of the 44 se-
quenced herpesviruses, all eight with GC contents of 68% or 
greater have a tropism for the nervous system. (The eight 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). GC content as measured in a sliding 120 bp window 
shown in representative regions of the HSV-1 genome (between 
UL42-UL46 and US5-US10). Note the presence of pronounced 
local minima in GC content in certain intergenic regions such as 
UL42-UL43 and UL43-UL44, but not in others such as US6-US7. 38    The Open Biochemistry Journal, 2007, Volume 1  Jay C. Brown 
Table 3.  Intergenic Regions with Genome-Like GC Content
a 
Intergenic 
Region 
Local 
GC min
b 
CACACA TTAAAA 
RL1-RL2 No  No  Yes  (2) 
RL2 (ex 2)-UL1  Yes  Yes (2)  No 
UL4-UL5 No  No  No 
UL8-UL9 No  No  No 
UL12-UL13 No  No  No 
UL14-UL15 (ex 1)  No  No  No 
UL16-UL17 No  No  No 
UL17-UL15 (ex 2)  No  No  No 
UL18-UL19 No  No  No 
UL19-UL20 No  Yes  No 
UL28-UL29 No  Yes  No 
UL29-UL30 Yes  No  No 
UL33-UL34 No  No  No 
UL34-UL35 No  Yes  No 
UL37-UL38 No  No  No 
UL39-UL40 No  No  No 
UL41-UL42 Yes  No  No 
UL43-UL44 Yes  Yes  No 
UL46-UL47 No  No  No 
UL47-UL48 Yes  Yes  No 
UL48-UL49 No  No  No 
UL51-UL52 No  No  No 
UL53-UL54 No  No  No 
UL56-RL2 Yes  No  No 
RS1-US1 Yes  No  No 
US2-US3 No  No  Yes 
US8-US9 No  Yes  Yes 
US11-US12 No  No  No 
US12-RS1 Yes  No  No 
 Total   8  8  4 
 Total per 10,000 bp  4.1  4.1  2.0 
aIntergenic regions with genome-like GC content are those with GC contents in the range of 62.1%-81.5%.  
bLocal GC minima are those identified by visual inspection of the GC content trace as defined in a sliding 120 bp window as shown in Fig. (4).  
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Table 4.  Intergenic Regions with Reduced GC Content
a 
Intergenic 
 Region 
Local 
GC Min
b 
CACACA TTAAAA 
UL2-UL3 Yes  No  No 
UL3-UL4 Yes  No  No 
UL7-UL8  No Yes No 
UL10-UL11 Yes  Yes  Yes  (2) 
UL15 (ex 1)-UL16  No  Yes (2)  No 
UL15 (ex 2)-UL18  Yes  Yes  No 
UL20-UL21 Yes  No  No 
UL21-UL22 No  No  No 
UL22-UL23 Yes  No  No 
UL24-UL25 Yes  No  No 
UL25-UL26 No  No  No 
UL26-UL27 Yes  Yes  (3)  Yes 
UL35-UL36 Yes  No  Yes 
UL36-UL37 No  No  No 
UL38-UL39 Yes  Yes  No 
UL40-UL41 No  No  No 
UL42-UL43 Yes  Yes  (2)  No 
UL44-UL45 Yes  No  Yes 
UL45-UL46 Yes  Yes  No 
UL50-UL51 Yes  Yes  No 
UL54-UL55 No  No  No 
UL55-UL56 Yes  Yes  No 
US1-US2 Yes  No  No 
US3-US4 No  No  No 
US4-US5  No Yes No 
US5-US6 Yes  Yes  Yes 
US6-US7 No  No  No 
US7-US8 Yes  No  No 
US9-US10 Yes  No  No 
 Total  19  16  6 
 Total per 10,000 bp  28.4  23.9  9.0 
aIntergenic regions with reduced GC content are those with GC contents in the range of 46.3%-61.7%.  
bLocal GC minima are those identified by visual inspection of the GC content trace as defined in a sliding 120 bp window as shown in Fig. (4).  
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Table 5.  CA Repeat and TTAAAA Retrotransposition Insertion Sites in the HSV-1 Genome 
Sequences Expected
a Observed 
CACACA (total)  49  79 
CACACA (in genes)  39  55 
CACACA (intergenic regions)  10  24 
TTAAAA (total)  5  28 
TTAAAA (in genes)  4  18 
TTAAAA (intergenic regions)  1  10 
aStatistically expected sequence numbers were calculated based on both strands of the 152,261 bp HSV-1 genome with 68% GC content. A 16%; T 16%; G 34%; C 34%. Calculated 
values were rounded to the nearest whole number. The proportions of gene and intergene regions in the HSV-1 genome were taken as 79% and 21%, respectively [1, 2].  
are: HSV-1, 68%; HSV-2, 70%; cercopithecine herpesvirus 
1, 74%; cercopithecine herpesvirus 2, 70%; cercopithecine 
herpesvirus 16, 76%; bovine herpesvirus 1 72%; bovine 
herpesvirus 5, 74%; pseudorabies virus, 73%.) In contrast, 
varicella-zoster virus (VZV) has a comparatively low GC 
content (46%) despite the fact that it becomes latent in neu-
rons [26]. The ability of VZV to produce such infections 
despite a low GC content may be due at least in part to the 
diversity of ganglia in which latent infections occur. Latent 
VZV infections are found in ganglia along the entire length 
of the central neural axis [26] while those of HSV-1 and 
HSV-2 are concentrated in a more restricted number of gan-
glia (e.g. the trigeminal in the case of HSV-1).  
Retrotransposition and Reduced GC Intergenic Regions 
  The existence of a population of intergenic regions with 
reduced GC content may also be related to retrotransposition 
events in neurons. Among the ways herpesviruses are 
thought to adapt to environmental change, on an evolution-
ary time scale, is by incorporating entire genes from the host 
cell genome. Evidence for such incorporations has been ob-
tained most recently in the case of certain gammaherpesvi-
ruses [3, 27-29]. Because the incorporated genes lack in-
trons, it is presumed that their incorporation occurs by way 
of a cDNA intermediate and L1 retrotransposition. In the 
case of HSV-1, the existence of intergenic regions with re-
duced GC content would be preferred as sites for gene inser-
tion due to the greater probability that they will contain AT-
rich L1 insertion sequences. Such regions would arise by 
default if their creation involved simply resisting the evolu-
tionary pressure favoring increased GC content. Evidence for 
preference of TTAAAA sequences in reduced GC compared 
to genome-like intergenic regions is described in this study 
(Tables 3 and 4). Six TTAAAA sequences are found in 6688 
bp of reduced GC intergenic DNA while 4 are found in 
19,651 bp of genome-like intergenic sequence.  
Experimental Tests 
  In the future it should be possible to test the idea ex-
pressed here that a high GC content is involved in resistance 
of the HSV-1 genome to invasion by L1 retrotransposons. As 
noted above, it is now possible to observe L1 transposition in 
cultured cells with the L1 element derived either from the 
cell genome or from a transfected plasmid [11, 24, 30]. Simi-
lar tests with herpesvirus-infected cells should demonstrate 
that L1 transposition into the virus genome occurs at a higher 
rate in low GC compared to high GC viruses. In HSV-1-
infected cells, transposition should occur preferentially into 
reduced GC intergene regions and should avoid genes.  
Local GC Minima and CA Repeats 
  Determination of the HSV-1 GC content in a 120 bp 
window was carried out as a supplement to measurements of 
the gene and intergene values. It was expected that intergenic 
regions might have a reduced GC content because of the 
measurements described above and also because intergenic 
regions are often the sites of AT-rich polyadenylation signals 
(AATAAA). In spite of such expectations, it was neverthe-
less noteworthy that GC minima were as pronounced and as 
focused on intergenic regions as the results demonstrated 
(Fig.  4). Intergenic regions with pronounced GC minima 
were found throughout the HSV-1 genome with a preference 
for reduced GC intergenic sequences as shown in Tables 3 
and 4. Further information about the function of intergenic 
GC minima might best be pursued by examining the ge-
nomes of other viruses for this feature, and appropriate stud-
ies are now underway in our laboratory.  
  CA dinucleotide repeats are an abundant feature of the 
human genome where they account for ~0.3% of the total 
sequence [10, 31]. Most occur in microsatellite sequences, 
but others are involved in functions such as regulation of 
gene expression [32, 33], control of alternative mRNA splic-
ing [34, 35] and mRNA stability [36]. Such functions depend 
on the ability of CA repeats to bind heterogeneous nuclear 
ribonucleoprotein L (hnRNP L; [33, 36]). In the HSV-1 ge-
nome, one CACACA sequence has been identified within 
the thymidine kinase coding region (UL23) where it acts by 
way of hnRNP L binding to enhance mRNA polyadenylation 
and nuclear export of intronless mRNAs [36]. Others of the 
55 coding region CACACA sequences may act in the same 
or a similar way. CACACA sequences are also found in in-
tergenic DNA. These are located throughout the HSV-1 ge-
nome with most (16 of 24) occurring in reduced GC inter-
genic regions (Tables 3 and 4). Analysis of deletions in such 
CACACA sequences suggests itself as a promising way to 
identify their function.  
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